Initiative during 2019 baseball postseason highlights Chris’ personal story and the profound consequences that can result from OA knee pain BURLINGTON, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics (Nasdaq:FLXN) is teaming up with Chris Dickerson, a former New York Yankees
BURLINGTON, Mass. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Adam Muzikant , Ph.D., Senior Vice President, Business Development, will present at the annual Cell & Gene Meeting on the Mesa in Carlsbad, California . Dr.
Interactive memorial developed by the National Safety Council pays tribute to more than 22,000 victims of the opioid crisis and offers resources to help stem the epidemic Exhibit will be on display Sept. 23-28 at the Roosevelt Field Mall in Garden City, NY BURLINGTON, Mass., Sept.
Flexion’s new locally delivered product candidate, FX301, will combine Xenon’s NaV1.7 inhibitor, XEN402, with a novel thermosensitive hydrogel FX301 is a potential first-in-class therapy with the aim of providing pain relief via peripheral nerve block for up to a week following surgery while
BURLINGTON, Mass. , Sept. 06, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to nine new employees consisting of an aggregate of 25,900 stock options and 4,350 restricted stock units. The Compensation Committee of the Board of Directors
BURLINGTON, Mass. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo Securities 2019 Healthcare Conference in Boston,
Company reported ZILRETTA ® ( triamcinolone acetonide extended-release injectable suspension) net sales of $17.0 million in Q2 representing 60% growth over Q1 Completed debt financing, which replaces previous term loan and provides up to $60 million in non-dilutive capital Results from nonclinical
BURLINGTON, Mass. , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 11 new employees consisting of an aggregate of 68,650 stock options and 11,525 restricted stock units. The Compensation Committee of the Board of Directors
BURLINGTON, Mass. , July 30, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2019 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2019 . Flexion’s management will host a conference call at
An analysis of clinical trial data indicates ZILRETTA reduced pain with similar improvements observed after each of two injections in patients with knee OA classified as Kellgren-Lawrence (KL) Grades 2-4 >80% of KL Grade 4 patients entering the trial with moderate to severe knee pain subsequently
